INTRODUCTION
============

Since its development in the late 1990s in Japan, endoscopic submucosal dissection (ESD) has increasingly been established as a promising procedure for epithelial neoplasm of the gastrointestinal (GI) tract.[@b1-gnl-09-52],[@b2-gnl-09-52] In contrast to endoscopic mucosal resection (EMR), ESD enables *en bloc* resection regardless of lesion size permitting a curative resection rate, and *en bloc* resection of early gastric cancer (EGC) is associated with a reduction in tumor recurrence.[@b2-gnl-09-52]--[@b4-gnl-09-52]

However, ESD demands advanced endoscopic techniques with lengthy procedure time. Besides, ESD is associated with a higher rate of complication such as perforation and bleeding compared to EMR.[@b5-gnl-09-52]--[@b7-gnl-09-52]

Post-ESD bleeding is one of the major concerns of endoscopists performing ESD. Although the frequency of complications in ESD has been decreased with improvements in technique and instrumentation, post-ESD bleeding has been reported in about 5% of cases.[@b4-gnl-09-52],[@b8-gnl-09-52],[@b9-gnl-09-52] Endoscopists continue their efforts to decrease the rate of post-ESD bleeding. Takizawa *et al*.[@b10-gnl-09-52] demonstrated that preventive coagulation of visibly exposed vessels on artificial ulcer decreased the post-ESD bleeding rate even if there was no evidence of bleeding at the end of ESD. Recently, post-ESD coagulation, regardless of the presence of bleeding at visible vessels on the resected area, is routinely performed.

In the same vein, a second-look endoscopy is routinely performed the next day or later after ESD in most hospitals to check for the possibility of post-ESD bleeding and to perform prophylactic hemostasis at the high risk lesion (such as the visible vessel) of rebleeding.[@b11-gnl-09-52] However, there has been little evidence that second-look endoscopy is needed to prevent delayed post-ESD bleeding. A few previous studies were controversial and they did not make pure comparisons between the groups with or without the second-look endoscopy.[@b11-gnl-09-52],[@b12-gnl-09-52] Therefore, we conducted a retrospective study to evaluate whether a second look endoscopy was necessary for preventing delayed post-ESD bleeding.

MATERIALS AND METHODS
=====================

1. Subjects
-----------

A total of 550 lesions with a histologic diagnosis of gastric epithelial neoplasms (338 EGCs and 212 gastric adenomas) in 502 patients (372 men and 130 women) were treated with ESD at Samsung Medical Center between 18 August 2009 and 18 August 2010. Among them, 547 lesions (335 EGCs and 212 gastric adenomas) were included after exclusion of three lesions of post-ESD bleeding within 24 hours.

ESD was principally indicated for possible node negative EGCs according to the criteria of Soetikno *et al*.[@b13-gnl-09-52] based on endoscopic findings including chromoendoscopy with biopsy and computed tomography findings. In cases of gastric adenomas, ESD was performed because lesions histologically diagnosed high grade dysplasia, may have contained foci of cancer, or patients strongly wanted the lesion to be resected. All ESDs were performed by two experienced endoscopists. Before ESD procedure, all patients provided written informed consent.

2. ESD procedure
----------------

The patients receiving anticoagulants or antiplatelets were instructed to stop taking them for 4 days or 1 week before the procedure. When there were more than two lesions in one stomach, the operator decided on a one stage or two stage procedure depending on the level of difficulty.

All ESD procedures were carried out under sedation with the intravenous administration of either midazolam combined with pethidine or propofol just before the procedure, and oxygen saturation and blood pressure were monitored.

ESD was performed using the following procedure. In brief, marking dots were made circumferentially at approximately 5 mm lateral to the margin of the lesion using a Needle knife (KD-1L-1, Olympus, Tokyo, Japan; Needle papillotome, MTW Endoscopy, Wesel, Germany) or a Dual knife (KD-650U; Olympus). After marking, a submucosal injection of saline mixed with epinephrine and indigocarmine was performed around the lesion to lift it off the muscle layer. If the tumor was located on the upper two-thirds of the stomach, a submucosal solution containing 10% glycerin was used. Then, an initial incision of mucosa was made with either a Needle knife or a Dual knife to allow insertion of the tip of the knife into the submucosa. After the initial incision, a circumferential mucosal incision was performed 5 mm outside the marking dots to separate the lesion from the surrounding nonneoplastic mucosa. This step was done using an electrosurgical knife such as the Needle knife, insulated-tipped (IT) knife (KD-610L; Olympus), or Dual knife with the use of an electrosurgical generator. After the circumferential incision, an additional submucosal injection was performed beneath the lesion. Finally, the submucosal connective tissue just beneath the lesion was directly dissected using an electrosurgical knife such as a Needle knife, an IT knife, or a Dual knife. The knife was chosen by preference of the operator. Hemostatic forceps (FD-410LR; Olympus) or hemoclips were used to control bleedings during resection. After dissection, visible vessels on the resected lesion were cauterized by Hemostatic forceps for the purpose of prophylactic hemostasis.

During and until 1 day after the procedure, a proton pump inhibitors (PPIs) or an histamine-2 receptor antagonists (H~2~RAs) were given via parental route and then standard dose of PPIs was prescribed for 4 weeks. The patients were allowed to take sips of water the day after the procedure and eat a light meal 2 days after if there was no problem.

A second-look endoscopy was performed 2 days after ESD before beginning meals only in patients who were enrolled in a prospective study for comparison between H~2~RAs and PPIs in the prevention of bleeding after ESD (this study was accepted in *Hepatogastroenterology*. In this study, there was no difference between the H~2~RAs and PPIs). If adherent clots or visible vessels with or without bleeding were observed during second look endoscopy, prophylactic hemostasis using Hemostatic forceps was done. The patient who underwent hemostasis during second-look endoscopy was allowed a light meal after being checked by endoscopy the next day.

3. Definitions
==============

Post-ESD bleeding was defined as follows: if there was obvious hematemesis, melena, or hematochezia after ESD, or the level of hemoglobin decreased over 2.0 g/dL within 24 hours after ESD, which required endoscopic treatment.

Delayed bleeding was defined as post-ESD bleeding diagnosed later than 24 hours after ESD. Flow charts for inclusion in each analysis are shown in [Fig. 1](#f1-gnl-09-52){ref-type="fig"}.

4. Statistical analysis
=======================

The univariate analysis was performed for comparison of patient-related, tumor-related and procedure-related factors. Differences in the means of continuous data such as age, size, and procedure times were compared using Student t-tests. Categorical data such as sex, macroscopic type, and histologic type, were compared using the chi-square test and Fisher exact test.

p-values of \<0.05 were considered statistically significant. If there was more than one predictor with a significant difference by univariate analysis, multivariate analysis by using a logistic regression model was planned.

RESULTS
=======

1. Clinical and endoscopic characteristics in a second-look and no second-look group
------------------------------------------------------------------------------------

A total of 547 lesions (335 EGCs and 212 gastric adenomas) in 499 patients (370 men and 129 women) were finally evaluated. A second-look endoscopy was performed in 194 lesions (second-look group). The baseline characteristics of subjects and lesions in both groups are summarized in [Table 1](#t1-gnl-09-52){ref-type="table"}. Mean age was 62.4±9.8 years (median age, 63 years; range, 32 to 84 years). In a second-look group, mean age was younger than no second-look group (58.8±8.8 vs 64.4±9.7, p\<0.01). Patient-related factors such as sex, comorbidity, and use of anticoagulants or antiplatelet agents were not statistically significant between the second-look and the no second-look groups.

The lesions were distributed similarly in both groups, most commonly in the lower third and lesser curvature side of the stomach. The histologic and macroscopic type were also not significantly different in both groups. The size of the lesions and resected specimens after ESD were measured in the longest axis. The size of the lesion in the second-look group was shorter than in the no second-look group (p=0.059). In the second-look group, *en bloc* resection rate was higher (98.5% vs 94.1%, p=0.016) and procedure time was also shorter than in the no second-look group (57.6±32.5 minutes vs 70.7±41.6 minutes, p\<0.01). In the second-look group, PPIs were administered to more patients than in the no second-look group (p\<0.01).

The hospitalization period for the second-look group was not delayed compared to the no second-look group (5.9±2.5 days vs 6.0±2.7 days, p=0.651).

2. Risk factors of delayed bleeding in a second-look and no second-look group
-----------------------------------------------------------------------------

Delayed post-ESD bleeding occurred in 11 out of 547 lesions (2%). The occurrence rate of delayed post-ESD bleeding was not significantly different between the second-look group and the no second-look group (2/194 lesions \[1%\] vs 9/353 lesions \[2.5%\], p=0.343). All delayed bleeding was successfully managed with only endoscopic treatment. No delayed post-ESD bleeding was followed by rebleeding.

The univariate analysis of variables for delayed post-ESD bleeding is shown in [Table 2](#t2-gnl-09-52){ref-type="table"}. There were no significant differences between the delayed bleeding group and nondelayed bleeding group in age, sex, comorbidity, use of anticoagulants or anti-platelets, location of tumor, macroscopic type of tumor, *en bloc* resection rate, or procedure time. However, the size of the tumors was significantly larger in the delayed post-ESD bleeding group (22.8±9.9 vs 15.1±10.5, p\<0.05). Ten out of 11 lesions in the delayed post-ESD bleeding group were larger than 15 mm in the size of the tumors (90.9% vs 41.6%, p=0.001). Also, the hospital stay was significantly longer in the delayed post-ESD bleeding group (10.2±5.8 vs 5.9±2.5, p=0.033). Furthermore, in the delayed bleeding group, there were no significant difference between the second-look group and the no second-look group in the patient and lesion-related factors.

In the second-look group with delayed post-ESD bleeding, one delayed bleeding occurred one day after prophylactic hemostasis for adherent hematoma on the ulcer base during the second-look endoscopy. The other occurred 10 days after second-look endoscopy without prophylactic hemostasis; however, this event developed after the patient underwent cardiovascular surgery 10 days after ESD.

In the no second-look group, nine delayed post-ESD bleeding were occurred on mean 3.4 days (median, 2 days; range, 1.5 to 12.0 days) after ESD. Bleeding findings, including one spurting, one oozing, two exposed vessels, and five adherent clots were observed.

3. Outcomes of prophylactic hemostasis in a second-look endoscopy
-----------------------------------------------------------------

In the second-look group, 22 of the 194 lesions were performed prophylactic hemostasis for Forrest classification[@b14-gnl-09-52] Ia to IIb lesions including four blood oozing, six visible vessels without any signs of hemorrhage, and 12 adherent clots or hematoma.

The characteristics of patients and lesion-related factors were not different between the prophylactic hemostasis group and the nonprophylactic hemostasis groups ([Table 3](#t3-gnl-09-52){ref-type="table"}).

The mean hospital stay was longer in patients with prophylactic hemostasis than in patients without prophylactic hemostasis, but there was no statistical significance (6.8±1.4 days vs 5.4±1.2 days, p=0.080) ([Table 4](#t4-gnl-09-52){ref-type="table"}).

DISCUSSION
==========

In the present study, we demonstrated that a second-look endoscopy after ESD did not reduce the delayed post-ESD bleeding even though prophylactic hemostasis for high risk lesions of rebleeding was performed during second-look endoscopy.

There were several studies about efficacy of routine second-look endoscopy for acute nonvariceal upper GI bleeding, and they still yielded conflicting results.[@b15-gnl-09-52],[@b16-gnl-09-52] Recently, meta-analysis data have suggested that routine second-look endoscopy with thermal coagulation reduced recurrent peptic ulcer bleeding, although these data failed to prove advantages in the clinical outcomes of patients with peptic ulcer bleeding.[@b17-gnl-09-52],[@b18-gnl-09-52] These results support the universal validity of second-look endoscopy after ESD for preventing delayed post-ESD bleeding. In addition, routinely performed preventive coagulation of visibly exposed vessels on artificial ulcer, regardless of the presence of bleeding at the end of ESD, could be provided for additional evidence of second-look endoscopy after ESD.[@b10-gnl-09-52]

Recently, a few studies were reported about the usefulness of second-look endoscopy after ESD for preventing delayed post-ESD bleeding. Goto *et al*.[@b11-gnl-09-52] found that delayed bleeding occurred with similar probability between the conditions before and after second-look endoscopy and they suggested that a second-look endoscopy after ESD would contribute little to the prevention of delayed bleeding. In another study by Kim *et al*.,[@b12-gnl-09-52] they reported that more delayed bleedings occurred before second-look endoscopy than after, and they suggested that a second-look endoscopy may have value for preventing delayed bleeding. Likewise, these studies showed conflicting results. However, the most important point in all of this is that they enrolled only patients who underwent second-look endoscopy and did not make a pure comparison between the groups with or without the second-look endoscopy. As a result, they compared only the rates of bleeding between before and after second look endoscopy.

In this study, we compared patients who underwent second-look endoscopy with patients who did not undergo second-look endoscopy. We also evaluated the outcomes between the groups with or without prophylactic hemostasis during second-look endoscopy. We found that the occurrence rate of delayed post-ESD bleeding was not different between the second-look group and the no second-look group. Furthermore, in the second-look group, delayed post-ESD bleeding occurred in both groups with or without prophylactic hemostasis. In a second-look group with prophylactic hemostasis, hospital stay tended to be prolonged more than it was with the second-look group without prophylactic hemostasis. In this study, the only predictor of delayed bleeding was tumor size, regardless of second-look endoscopy after ESD. Recently, Ryu *et al*.[@b19-gnl-09-52] and Kim *et al*.[@b20-gnl-09-52] reported prospective randomized controlled trials about the efficacy of second look endoscopy for prevention of delayed bleeding after ESD. They compared second look endoscopy group with non-second look endoscopy group, and showed that the second look endoscopy was not decreased delayed bleeding after ESD, even though the proportion of enrolled EGCs in their studies was relatively small and Ryu *et al*.[@b19-gnl-09-52] enrolled relatively small number of cases. Furthermore, Kim *et al*.[@b20-gnl-09-52] reported that a large tumor size was the only risk factor for delayed bleeding. It was similar with our study and previous studies about factors related to delayed bleeding following ESD.[@b21-gnl-09-52] The present study supported the Kim *et al*.[@b20-gnl-09-52] result.

This study had a few limitations. First, it was a retrospective study from a single center. However, the number of cases was not small compared with previous studies to evaluate the risk of post-ESD bleeding.[@b8-gnl-09-52],[@b11-gnl-09-52],[@b22-gnl-09-52],[@b23-gnl-09-52] In this study, only two experts performed ESD for gastric neoplasms, and the bias induced by endoscopists was relatively low. Second, patients who underwent a second-look endoscopy were enrolled in a prospective study for comparison between the H~2~RAs and PPIs in the prevention of bleeding after ESD (this study was accepted in *Hepatogastroenterology*). However, in this study, there was no difference between the H~2~RAs and PPIs in preventing bleeding from artificial ulcers after ESD. The effects of the H~2~RAs and PPIs in the prevention of bleeding after ESD remain controversial, although there have been several previous studies.[@b23-gnl-09-52],[@b24-gnl-09-52] In this study, there was also no difference between delayed bleeding group and the nondelayed bleeding group according to administration of PPIs or H~2~RAs after ESD (p=1.000).

In conclusion, we suggest that a second-look endoscopy to prevent delayed bleeding after ESD is useless because it could not reduce the rate of delayed bleeding even though prophylactic hemostasis was performed, repeat endoscopy after ESD make patients feel uncomfortable, and it can delay the time to start eating after ESD. However, further studies are needed to select the patients who is helpful to undergo a second look endoscopy for prevention of delayed bleeding after ESD.
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###### 

Characteristics of Patients and Lesions in Groups

  Characteristic                                 Total (547 lesions)   2nd-look (194 lesions)   No 2nd-look (353 lesions)   p-value
  ---------------------------------------------- --------------------- ------------------------ --------------------------- ---------
  Age                                                                                                                       0.000
   Median (range)                                63 (32--84)           60 (32--75)              66 (34--84)                 
   Mean±SD                                       62.4±9.8              58.8±8.8                 64.4±9.7                    
  Male sex                                       408 (74.6)            148 (76.3)               260 (73.7)                  0.539
  Comorbidities                                                                                                             
   Hypertension (present)                        203 (37.1)            66 (34.0)                137 (38.8)                  0.309
   Diabetes mellitus (present)                   96 (17.6)             33 (17.0)                63 (17.8)                   0.907
   Heart disease (present)                       11 (2.0)              1 (0.5)                  10 (2.8)                    0.107
  Anticoagulants/platelets (used)                53 (9.7)              19 (9.8)                 34 (9.6)                    1.000
  Histologic type                                                                                                           
   Adenoma/adenocarcinoma                        212/335               68/126                   144/209                     0.200
  Location                                                                                                                  
   Upper/mid/lower third                         38/167/342            9/60/125                 29/107/217                  0.287
   AW/PW/LC/GC                                   95/89/231/132         26/29/93/46              69/60/138/86                0.146
  Macroscopic type                                                                                                          
   Elevated/flat or depressed                    411/136               137/57                   274/79                      0.079
  Size of the tumor, mm                          15.3±10.5             14.1±9.3                 15.9±11.1                   0.059
  Size of the resected specimen, mm              43.2±13.3             42.7±11.6                43.5±14.2                   0.489
  Resection style, *en bloc*/piecemeal           523/24                191/3                    332/21                      0.016
  Procedure time, min                            66.0±39.1             57.6±32.5                70.7±41.6                   0.000
  Delayed post-ESD bleeding                      11 (2.0)              2 (1.0)                  9 (2.5)                     0.343
  Antiulcer medication after ESD, PPIs/H~2~RAs   129/418               92/102                   37/316                      0.000

Data are presented as mean±SD or number (%).

SD, standard deviation; AW, anterior wall; PW, posterior wall; LC, lesser curvature; GC, great curvature; ESD, endoscopic submucosal dissection; PPIs, proton pump inhibitors; H~2~RAs, histamine-2 receptor antagonists.

###### 

Univariate Analysis of Predictors on Delayed Post-Endoscopic Submucosal Dissection Bleeding

                                                 Occurred (11 lesions)   Not occurred (536 lesions)   p-value                             
  ---------------------------------------------- ----------------------- ---------------------------- ----------- ------- --------------- -------
  Age                                            58.3±9.5                52.0±18.4                    59.7±7.7    0.660   62.5±9.7        0.156
  Male sex                                       9 (81.8)                2 (100.0)                    7 (77.8)    1.000   399 (74.4)      0.738
  Comorbidities                                                                                                                           
   Hypertension (present)                        4 (36.4)                1 (50.0)                     3 (33.3)    1.000   199 (37.1)      1.000
   Diabetes mellitus (present)                   1 (9.1)                 0                            1 (11.1)    1.000   95 (17.7)       0.699
   Heart disease (present)                       1 (9.1)                 0                            1 (11.1)    1.000   10 (1.9)        0.202
  Anticoagulants/platelets (used)                2 (18.2)                1 (50.0)                     1 (11.1)    0.345   51 (9.5)        0.289
  Histologic type                                                                                                                         
   Adenoma/adenocarcinoma                        4/7                     0/2                          4/5         0.491   208/328         1.000
  Location                                                                                                                                
   Upper/mid/lower third                         0/2/9                   0/1/1                        0/1/8       0.345   38/165/333      0.366
   AW/PW/LC/GC                                   1/2/6/2                 0/0/2/0                      1/2/4/2     0.565   94/87/225/130   0.793
  Macroscopic type                                                                                                                        
   Elevated/flat or depressed                    7/4                     1/1                          6/3         1.000   404/132         0.479
  Size of the tumor, mm                          22.8±9.9                28.0±14.1                    21.7±9.4    0.441   15.1±10.5       0.016
   ≥15                                           10 (90.9)               2 (100.0)                    8 (88.9)    1.000   223 (41.6)      0.001
   ≥20                                           7 (63.6)                1 (50.0)                     3 (66.7)    1.000   136 (25.4)      0.009
  Size of the resected specimen, mm              48.0±13.7               50.0±14.1                    47.6±13.4   0.832   43.1±13.3       0.226
  Resection style, *en bloc*/piecemeal           11/0                    2/0                          9/0         1.000   512/24          1.000
  Procedure time, min                            64.3±19.8               77.5±13.4                    61.3±20.3   0.321   66.1±39.4       0.879
  Antiulcer medication after ESD, PPIs/H~2~RAs   2/9                     1/1                          1/8         0.345   127/409         1.000

Data are presented as mean±SD or number (%).

AW, anterior wall; PW, posterior wall; LC, lesser curvature; GC, great curvature; ESD, endoscopic submucosal dissection; PPIs, proton pump inhibitors; H~2~RAs, histamine-2 receptor antagonists.

###### 

Characteristics of the Prophylactic Hemostasis and Nonhemostasis Groups during Second-Look Endoscopy

                                                  Hemostasis (22 lesions)   Nonhemostasis (172 lesions)   p-value
  ----------------------------------------------- ------------------------- ----------------------------- ---------
  Age                                             55.5±10.3                 59.2±8.6                      0.062
  Male sex                                        19 (86.4)                 129 (75.0)                    0.297
  Comorbidities                                                                                           
   Hypertension (present)                         8 (36.4)                  58 (33.7)                     0.814
   Diabetes mellitus (present)                    6 (27.3)                  27 (15.7)                     0.223
   Heart disease (present)                        0                         1 (0.6)                       1.000
  Anticoagulants/platelets (used)                 2 (9.1)                   17 (9.9)                      1.000
  Histologic type                                                                                         
   Adenoma/adenocarcinoma                         5/17                      63/109                        0.241
  Location                                                                                                
   Upper/mid/lower third                          1/4/17                    8/56/108                      0.379
   AW/PW/LC/GC                                    2/1/16/3                  24/28/77/43                   0.094
  Macroscopic type                                                                                        
   Elevated/flat or depressed                     14/8                      123/49                        0.462
  Size of the tumor, mm                           13.2±8.5                  14.3±9.4                      0.629
  Size of the resected specimen, mm               41.5±10.0                 42.8±11.8                     0.613
  Resection style, *en bloc*/piecemeal            22/0                      169/3                         1.000
  Procedure time, min                             59.5±30.9                 57.4±32.8                     0.772
  Anti-ulcer medication after ESD, PPIs/H~2~RAs   10/12                     82/90                         1.000

Data are presented as mean±SD or number (%).

AW, anterior wall; PW, posterior wall; LC, lesser curvature; GC, great curvature; ESD, endoscopic submucosal dissection; PPIs, proton pump inhibitors; H~2~RAs, histamine-2 receptor antagonists.

###### 

Comparison of Hospital Stay according to Events

                              Hospital stay, days   p-value
  --------------------------- --------------------- ---------
  2nd-look endoscopy                                0.651
   Yes                        5.9±2.5               
   No                         6.0±2.7               
  2nd-look with hemostasis                          0.080
   Yes                        6.8±1.4               
   No                         5.8±2.6               
  Delayed post-ESD bleeding                         0.033
   Yes                        10.2±5.8              
   No                         5.9±2.5               

Data are presented as mean±SD.

ESD, endoscopic submucosal dissection.
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